This surging cash cow is still a six week old calf

April 18, 2024 Hello , It’s been more than a year since Ozempic stormed the celebrity headlines. Public acceptance has grown. Insurance companies are coming around. And sales have surged. But if you watch the news this week, you will see just the start of [something much bigger.]( Ozempic is in a class of drugs known as Glucagon Like Peptide 1 (GLP-1). All the big weight-loss drugs – including Maunjaro and Wegovy – are GLP-1’s too. But just like these diabetes drugs found a huge new market with a new application in weight loss, there are still many more applications to come. This week we got the perfect example. Zepbound, a GLP-1 drug and is a version of Maunjaro, was found to be an effective sleep apnea treatment in a Phase 3 clinical study. That adds another big potential market with an estimated 40 million Amercians suffering from it. And it shows there’s huge potential here. In the years ahead we may see successful applications for hundreds of other ailments including cardiovascular diseases. And as they become tied to medical conditions than just weight loss, health insurance companies will likely be more willing to pick up the tab for these drugs. All this together have set GLP-1 drugs on course to be the richest and most valuable drugs history. [Click here to see how these drugs could be a $1 trillion industry all by themselves.]( [READ MORE]( Dynamic Wealth Research 2010 West Avenue K #623 Lancaster, California 93536 © 2024 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]